Simplified Summary
Mazdutide (IBI362) is a synthetic peptide designed to act as a dual agonist at GLP-1 and glucagon receptors. Laboratory investigations have examined its activity profile across in vitro receptor binding assays and animal model systems, focusing on hepatic lipid biology and metabolic regulation.
In preclinical research, mazdutide has been studied for its effects on hepatic triglyceride content and circulating lipid fractions. Animal model studies have examined whether the glucagon receptor component contributes to increased lipolysis and altered fatty acid oxidation in liver tissue.
Key Findings Reported in Preclinical Models
- Reduction in hepatic fat content in preclinical non-alcoholic fatty liver disease models, with decreased hepatic triglyceride accumulation compared to vehicle controls.
- Modulation of circulating lipid profiles in animal model metabolic studies, influencing triglyceride and lipoprotein fractions through glucagon receptor-mediated effects.
- Body weight reductions in diet-induced obesity rodent models, with preclinical data suggesting additive contributions from both receptor axes.
- Glycaemic modulation in preclinical diabetic animal models, with GLP-1-mediated insulinotropic activity documented under glucose-stimulated conditions.
- In vitro receptor binding and signalling characterisation using cell-based assays to define relative agonist activity at GLP-1R and GCGR.
Introduction
Mazdutide was developed as part of a broader effort to engineer dual agonists that simultaneously engage GLP-1 and glucagon receptor systems. The scientific rationale draws on preclinical evidence that glucagon receptor activation drives hepatic fat mobilisation and increases energy expenditure, while GLP-1 receptor activity suppresses appetite and modulates insulin secretion.
The compound represents a contribution from Chinese pharmaceutical research to the dual incretin agonist landscape. Preclinical characterisation has proceeded through both in vitro and in vivo model systems examining receptor affinity, plasma stability, and metabolic effects in rodent models.
Research Applications
- Hepatic steatosis research in preclinical NAFLD rodent models, probing the mechanistic contributions of GLP-1 and glucagon receptor pathways.
- Lipid metabolism studies examining effects on circulating lipoprotein profiles and hepatic de novo lipogenesis.
- Comparative dual agonist pharmacology research alongside other GLP-1/glucagon and GLP-1/GIP compounds.
- In vitro receptor pharmacology using transfected cell systems expressing human GLP-1R and GCGR.
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.